Real Ventures is an early-stage venture firm focused on serving daring entrepreneurs with the ambition to create successful, global companies. Since 2007, Real Ventures has dedicated itself to building the Canadian startup ecosystem on the belief that people, not money, build game-changing companies. Real Ventures provides stage-specific guidance, mentorship, and access to networks and resources to fast-track founders’ personal and company growth. Real Ventures manages $325 million across five funds and its active portfolio of 100+ companies is currently valued at $10 billion. www.realventures.com

Real Ventures

FounderFuel is a mentor-driven venture accelerator that helps new startups make progress on the venture path. The company is a four-month intensive program supported by a network of veteran entrepreneurs, operators, and executives. The program pushes companies to refine visions, expand the network and rapidly accelerate output. FounderFuel was founded by Real Ventures in 2011 and is headquartered Montreal, Canada.

FounderFuel

Golden Ventures is a leading seed-stage venture capital fund, based in Toronto and investing across North America. We're here to support founders who are building the future. It is our job to take big risks on the world's most talented, driven and resilient founding teams who want to change the world.

Golden Ventures

Afore Capital backs product-centric founders at the pre-seed stage exclusively. The investment team brings 16 years of founding product experience (Android and Twitter) and 7 years of institutional investing experience (Founder Collective and Foundation Capital). Their sweet spot is the ~$1M pre-seed round, where they can lead the round as an institutional investor alongside high value angels.

Afore Capital

Geo-fund of the world-wide 500 Startups fund

500 Startups Canada

Radical Ventures is an early-stage venture capital firm investing in entrepreneurs applying deep technology to transform massive industries. With a primary focus on artificial intelligence, Radical Ventures partners with entrepreneurs with global ambition to build enduring companies. The firm is based in Toronto, Canada, with offices in London (UK), and Palo Alto (US)

Radical Ventures

The Ontario Centres of Excellence invests in projects and people to accelerate industry R&D to impact the Ontario economy through the commercialization of leading edge research.  OCE invests in - Industry-Academic collaborative research - Commercialization of academic research through licensing and spin off companies - Early stage seed financing of start-ups - Skills development for high quality personnel  The Ontario Centres of Excellence is a not-for-profit corporation founded in 1987. Core funding is provided by the Ontario Ministry of Research and Innovation

Ontario Centres of Excellence

Two Small Fish started as a way to recycle the experience, knowledge, and capital from our days as successful entrepreneurs to help the next generation of founders. What separates us from other venture firms is that each Two Small Fish partner is an engineer by training and an entrepreneur or operator by experience. We are proven serial entrepreneurs with multiple exits under our belt.

Two Small Fish Ventures

Inovia Capital is a venture capital firm that works with founders to create influential and permanent businesses. The team leverages an operator mindset to provide founders with support, mentorship, and access to a worldwide network. Inovia manages over US$2.2B with operations in Montreal, Toronto, Calgary, San Francisco, and London.

Inovia Capital

Gradient is a seed fund that focuses on supporting founders in the artificial intelligence sector. The firm collaborates closely with innovators to integrate AI into various business processes and drive technological advancements. Gradient aims to foster disruptive ideas that can redefine industries and enhance operational capabilities.

Gradient

F-Prime's roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, this venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.  Today, F-Prime's funds are larger and more global, but its teams are still small and local. F-Prime stays true to its entrepreneurial roots. In the US and Europe, F-Prime Capital Partners is investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, its sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai.   Together F-Prime brings a world of insight, domain expertise and relationships to support entrepreneurs. Without the pressure of fundraising from outside investors, F-Prime Capital Partners focuses all of its time finding and helping great entrepreneurs build important companies.

F-Prime Capital

Northleaf Capital Partners Ltd. (''Northleaf'') is Canada's largest independent global private equity fund manager and advisor.  Northleaf's predecessor, TD Capital Private Equity Investors, was the private equity fund of funds and co-investment arm of TD Bank Financial Group, one of North America's leading financial institutions.  Northleaf's clients include corporate and public pension plans, endowments, foundations, government agencies, financial institutions and family offices.  As a global private equity investor with strong Canadian roots and a long history of superior investment returns, Northleaf is dedicated to generating attractive, long-term investment returns through building enduring relationships with our investors, fund managers, business partners and colleagues based on trust, openness, respect and the highest standards of integrity and professionalism.  Northleaf's 40-person team, located in Toronto, Canada, London, UK, and Menlo Park, California, is focused exclusively on sourcing, selecting, evaluating, structuring, managing, monitoring and reporting on private equity fund investments and direct co-investments. Northleaf currently manages four global fund of funds and a series of customized private equity investment programs tailored to meet the specific needs of individual institutional investors.

Northleaf Capital Partners

TCV provides capital to growth-stage private and public companies in the technology industry. It also provides management teams with data-driven insights, sector expertise, access to world-class talent, and connections with category leaders.  Founded in 1995, the Silicon Valley-headquartered firm has invested more than $14 billion in over 350 growth-stage technology companies to date. Some of its most prominent portfolio company exits include Airbnb, Facebook, Netflix, Peloton, and Zillow.

Generation Investment Management is dedicated to investing, integrated sustainability research, and client alignment. The company believes the interests of shareholders, over time, will be best served by companies that improve financial returns by managing economic, social, and environmental performance. It also builds a global research platform to integrate sustainability research into fundamental financial analysis. The company's investment team was founded by bringing together investment analysts with leaders from the sustainability research field. Generation's investment approach is based on the conviction that sustainability risks and opportunities directly affect long-term business profitability.

Generation Investment Management

BDC Venture Capital is a major venture capital investor in Canada, active at every stage of the company's development cycle, from seed through expansion, with a focus on technology-based businesses that have high growth potential and that are positioned to become dominant players in their markets. The company helps create and develop strong Canadian businesses through financing, consulting services and securitization, with a focus on small and medium-sized enterprises. BDC Venture Capital has been involved in venture capital since 1975 and has to date invested in more than 400 companies involved in the areas of Life Sciences, Telecommunications, Information Technology and Advanced Technologies.

BDC Venture Capital

BenchSci

BenchSci uses AI to empower scientists to run more successful experiments to accelerate drug discovery. The company empowers scientists with advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology accelerates science pharmaceutical companies and over 4,300 research centers worldwide.

<div>Based in Canada, BenchSci offers AI solutions for preclinical life sciences research and development. The company&rsquo;s AI platform, ASCEND, is designed to improve the speed and success of research in preclinical drug development. This platform is known for its proprietary text and image-based machine-learning models that assist scientists in discovering biological connections and reducing experimental errors. It claims that the platform reduces the time to select antibodies and reagents for preclinical experiments from weeks to 30 seconds, narrowing choices from thousands to a few.</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

BenchSci trims headcount citing generative AI, economic conditions

<div>
 
 Based in Canada, BenchSci offers AI solutions for preclinical life sciences research and development. The company&rsquo;s AI platform, ASCEND, is designed to improve the speed and success of research in preclinical drug development. This platform is known for its proprietary text and image-based machine-learning models that assist scientists in discovering biological connections and reducing experimental errors. It claims that the platform reduces the time to select antibodies and reagents for preclinical experiments from weeks to 30 seconds, narrowing choices from thousands to a few.
 
 
 The company claims that early adopters of ASCEND have seen a 40% improvement in identifying new indications or targets and a 33% enhancement in recognizing risks to safety or efficacy. Further, its AI-assisted antibody selection, launched in 2017, was its first major product, focusing on reducing experimental failure through advanced data analytics​​​​.
 
 
 Key customers and partnerships
 
 
 As of March 2024, BenchSci reportedly had more than 50,000 platform users (from over 4,500 institutions globally and 16 of the top 20 pharmaceutical companies) and had identified over 78 million reagent use cases from over 400 vendors. Some key customers included Sanofi, Novo Nordisk, GSK, Novartis, Amgen, Takeda, Gilead, and Merck. 
 
 
 In addition, the company entered several key partnerships, including ThermoFisher Scientific (
 <a href="https://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-provide-antibody-publication-data-on-its-website-300675088.html">
 July 2018
 </a>
 ), Novus Biologicals (
 <a href="https://www.novusbio.com/about/press-release/bio-techne-partners-with-benchsci-to-enhance-its-available-publication-data-of-its-commercial-antibodies">
 October 2018
 </a>
 ), Qiagen and Eurofins. 
 
 
 Funding and financials
 
 
 In 
 <a href="https://sp-edge.com/updates/18885">
 May 2023
 </a>
 , BenchSci raised CAD 95 million (USD 70 million) in a Series D funding round led by Generation Investment Management. The funds were used to further develop and expand the capabilities of ASCEND. 
 
</div>

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris’s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

<div>
 
 Verge Genomics is a biotechnology company engaged in developing therapeutics for neurological diseases using human genomics and AI to accelerate drug discovery. The main target areas are Amyotrophic Lateral Sclerosis (ALS), Parkinson&rsquo;s Disease (PD), and Frontotemporal Dementia (FTD).&nbsp;
 
 
 It has built a proprietary all-human platform (unlike standard clinical trials that rely on animal data), called CONVERGE, that uses data sets from brain tissue samples of deceased patients with ALS and PD. While most drugs target only one gene at a time, the company claims its technology can identify hundreds of genes that cause disease and develop drugs that target all the genes at the same time. The company uses AI technology to optimize the drug discovery process as a whole.
 
 
 As of March 2024, Verge had one drug candidate in the clinical stage (Phase I) and 10 drug candidates in the discovery stage.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has partnerships with various tissue banks (such as Harvard University and University of Miami Miller School of Medicine) and several educational institutes and foundations (such as Target ALS, Answer ALS) that enabled its drug discovery platform.&nbsp;
 
 
 In addition, the company&rsquo;s customers include several pharmaceutical companies, such as 1) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-announces-research-collaboration-with-the-sheffield-institute-for-translational-neuroscience">
 Sheffield Institute for Translational Neuroscience (SITraN)
 </a>
 to accelerate the validation of novel drug targets and screening of drug compounds for Parkinson's disease (February 2021), 2) 
 <a href="https://sp-edge.com/updates/4146">
 Eli Lilly
 </a>
 to research and develop novel therapies to treat ALS (July 2021), 3) 
 <a href="https://sp-edge.com/updates/21707">
 Alexion
 </a>
 to identify novel drug targets for rare neurodegenerative and neuromuscular diseases (September 2023), and 4) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-and-the-pritzker-neuropsychiatric-disorders-research-consortium-form-cutting-edge-schizophrenia-research-collaboration">
 Pritzker Neuropsychiatric Disorders Research Consortium
 </a>
 to analyze data from schizophrenic patient&rsquo;s brain tissue with Verge&rsquo;s technology (October 2023).
 
 
 Funding and financials
 
 
 In December 2021, Verge raised USD 98 million in an oversubscribed 
 <a href="https://sp-edge.com/updates/7426">
 Series A
 </a>
 funding round led by BlackRock. The funds were used to scale up its pre-clinical and clinical candidate programs in the pipeline and enhance its lead therapeutics through clinical testing. 
 
</div>

Verge Genomics

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to design and run preclinical experiments.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response.

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

Includes companies that use GenAI as a core part of their product offering for drug discovery & development

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

BenchSci

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless